Novartis AG / CoStim Pharmaceuticals, Inc.

Solid Tumors (Immuno-Oncology)

Disease Overview

Immuno-oncology checkpoint blockade unleashes T cells against tumors by targeting inhibitory receptors such as PD-1, PD-L1, CTLA-4, and emerging next-generation targets. Approved checkpoint inhibitors transformed advanced melanoma, NSCLC, RCC, and several other tumor types, but the majority of patients still do not respond, driving demand for novel checkpoints and combination regimens.

Competitive Landscape

At deal closing in February 2014, the PD-1 race was led by Bristol-Myers Squibb's nivolumab (Opdivo, first global approval Japan July 2014) and Merck's pembrolizumab (Keytruda, US approval September 2014), with Roche/Genentech's atezolizumab (anti-PD-L1) and AstraZeneca's durvalumab close behind. Novartis was the conspicuous big-pharma absentee in checkpoint blockade despite owning the most-advanced CD19 CAR-T (CTL019/tisagenlecleucel) via its University of Pennsylvania alliance. CoStim, founded in 2012 by MPM Capital and Atlas Venture with Harvard scientific founders Arlene Sharpe, Gordon Freeman, and Vijay Kuchroo, gave Novartis a late-discovery PD-1 antibody plus additional checkpoint programs that could be paired with CTL019, addressing the strategic gap. The deal was modest in headline value but symbolically large—Novartis's formal entry into the checkpoint race—and reflected an industry pattern of buying scientific founder-led startups rather than building from scratch.